PlainPill

BPC-157 vs MK-2866 for recovery

Short answer: For recovery, users rate them about the same: 96% report improvement with BPC-157 (494 reports) and 96% with MK-2866 (78 reports).

BPC-157 has 0 meta-analyses and 0 randomized trials on PubMed; MK-2866 has 0 and 0.

Based on 1,613 reports about BPC-157 and 789 about MK-2866. Not medical advice.

BPC-157
Peptide
MK-2866
SARM
Users say it helped54%helped919 reports · high confidence37%helped489 reports · high confidence
Verdict
Mixed
Mixed
ResearchDResearch: NoneDResearch: None
Meta-analyses / RCTs0 / 00 / 0
Mainly used for
Recovery
% reporting improvement
96% (494)96% (78)
Pain & inflammation
% reporting improvement
86% (485)71% (31)
Performance
% reporting improvement
95% (61)87% (252)
Mood
% reporting improvement
65% (128)66% (64)
Digestion
% reporting improvement
84% (111)0% (2)
Common side effectsfatigue, anhedonia, anxiety, headachesuppression, fatigue, insomnia, headache
Typical dose reportedNot listedNot listed
BPC-157
What a user said
“after 2+ years of nothing working, this is the 1st thing to reverse significant muscle damage ... 40% increase in my range of motion, and nearly the same in muscle strength.”
Full BPC-157 profile →
MK-2866
What a user said
“I've taken LDG-4033 and Ostarine from Ceretropic and noticed slight psychoactive effects from both, immediately (within 30 minutes after dosing).”
Full MK-2866 profile →

Related comparisons

Percentages come from first-hand user reports and are not clinical outcomes. Talk to a doctor before starting, stopping or combining anything. How we rate